Loading…
Mereo BioPharma Group plc is projected to rise to $0.3413 by 2027, a +2% move from its current price of $0.335. MREO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.3214 | $0.3353 | $0.3498 | +0.08% |
| Jul 15 | $0.316 | $0.3356 | $0.3563 | +0.17% |
| Jul 16 | $0.312 | $0.3358 | $0.3614 | +0.25% |
| Jul 17 | $0.3088 | $0.3361 | $0.3659 | +0.33% |
| Jul 18 | $0.306 | $0.3364 | $0.3699 | +0.42% |
| Jul 19 | $0.3034 | $0.3367 | $0.3735 | +0.50% |
| Jul 20 | $0.3012 | $0.337 | $0.377 | +0.58% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3012 | $0.337 | $0.377 | +0.58% |
| Week 2 | $0.2892 | $0.3389 | $0.3972 | +1.17% |
| Week 3 | $0.2807 | $0.3409 | $0.4141 | +1.76% |
| Week 4 | $0.274 | $0.3429 | $0.4292 | +2.36% |
| Week 5 | $0.2684 | $0.3449 | $0.4433 | +2.96% |
| Week 6 | $0.2635 | $0.3469 | $0.4567 | +3.56% |
| Week 7 | $0.2593 | $0.349 | $0.4696 | +4.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Mereo BioPharma Group plc is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. Its portfolio includes Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease.
The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Mereo BioPharma Group plc (MREO) is currently priced at $0.3318 with a market capitalization of $52.96M and ranks 4300 in market position. The stock’s current price sits amid a near-term range and is accompanied by a bullish technical outlook in the near term. Forecasts show the 2026 average price at $0.3318, with a neutral sentiment for that year.
A major floor 29.3% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
Price is pressing into resistance (3.0% away) — a breakout level to watch.
A major ceiling 23.6% above — clearing it would confirm fresh momentum.
Key MREO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MREO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.3254 | Buy | $0.327 | Buy |
| MA 10 | $0.3232 | Buy | $0.3234 | Buy |
| MA 20 | $0.3154 | Buy | $0.318 | Buy |
| MA 50 | $0.2966 | Buy | $0.322 | Buy |
| MA 100 | $0.3267 | Buy | $0.443 | Sell |
| MA 200 | $0.9011 | Sell | $0.8323 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.13 | Neutral |
| Stoch RSI (14) | 81.13 | Sell |
| CCI (20) | 116.05 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 4.04 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.29 | Buy |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 57.16 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 0.33 | Buy |
| ADX (14) | 10.23 | Neutral |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is bullish with RSI(14) at 60. The stock trades above the SMA50 of $0.294 but well below the SMA200 of $0.9594, indicating stronger near-term momentum but longer-term weakness relative to the broad trend. Support is cited at $0.237 and resistance at $0.345, with a 30-day range of $0.2447 to $0.45.
Annualized volatility is high at 90%, reflecting substantial near-term price swings.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.237 | $0.335 | $0.4876 | 0% | Neutral | |
| $0.2578 | $0.3413 | $0.4855 | +2% | Neutral | |
| $0.2759 | $0.3825 | $0.5738 | +14% | Neutral | |
| $0.2721 | $0.3922 | $0.613 | +17% | Neutral | |
| $0.3146 | $0.4696 | $0.7594 | +40% | Bullish | |
| $0.3797 | $0.5853 | $0.975 | +75% | Bullish | |
| $0.3825 | $0.6078 | $1.04 | +81% | Bullish | |
| $0.3838 | $0.6277 | $1.10 | +87% | Bullish | |
| $0.3507 | $0.5897 | $1.06 | +76% | Bullish | |
| $0.3441 | $0.5944 | $1.08 | +77% | Bullish | |
| $0.446 | $0.8743 | $1.73 | +161% | Bullish | |
| $0.9356 | $2.08 | $4.64 | +521% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.237 | $0.335 | $0.4152 | +0.00% |
| August 2026 | $0.3033 | $0.3633 | $0.4507 | +8.46% |
| September 2026 | $0.2984 | $0.3614 | $0.456 | -0.52% |
| October 2026 | $0.2892 | $0.3537 | $0.4526 | -2.13% |
| November 2026 | $0.297 | $0.3662 | $0.474 | +3.51% |
| December 2026 | $0.2999 | $0.3726 | $0.4876 | +1.76% |
Click any year to see its month-by-month MREO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MREO is projected to trade between $0.237 and $0.4876, averaging $0.335 — a potential gain of 0% from today's $0.335. Price action looks broadly range-bound.
Mereo BioPharma Group plc's 2027 outlook centres on $0.3413, within a $0.2578 to $0.4855 range. That is up +2% on the projected 2026 average. That marks a +2% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, MREO could reach as high as $0.5738, with a base case around $0.3825 and support toward $0.2759 — roughly +14% from $0.335. Price action looks broadly range-bound.
Expect MREO to range from $0.2721 to $0.613 through 2029. The $0.3922 average target implies a +17% move from current prices. That is up +3% on the projected 2028 average. A consolidation phase looks the most probable path here.
The MREO price prediction for 2030 points to an average of $0.4696 (low $0.3146, high $0.7594) — a potential gain of +40% on today's $0.335. Momentum favours further upside here.
In 2031, MREO is projected to trade between $0.3797 and $0.975, averaging $0.5853 — a potential gain of +75% from today's $0.335. That is up +25% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Mereo BioPharma Group plc's 2032 outlook centres on $0.6078, within a $0.3825 to $1.04 range. That is up +4% on the projected 2031 average. That marks a +81% change versus current levels. Momentum favours further upside here.
By 2033, MREO could reach as high as $1.10, with a base case around $0.6277 and support toward $0.3838 — roughly +87% from $0.335. Buyers look set to stay in control over this stretch.
Expect MREO to range from $0.3507 to $1.06 through 2034. The $0.5897 average target implies a +76% move from current prices. That is -6% versus the projected 2033 average. Momentum favours further upside here.
The MREO price prediction for 2035 points to an average of $0.5944 (low $0.3441, high $1.08) — a potential gain of +77% on today's $0.335. Buyers look set to stay in control over this stretch.
In 2040, MREO is projected to trade between $0.446 and $1.73, averaging $0.8743 — a potential gain of +161% from today's $0.335. That is up +47% on the projected 2035 average. Momentum favours further upside here.
Mereo BioPharma Group plc's 2050 outlook centres on $2.08, within a $0.9356 to $4.64 range. That is up +138% on the projected 2040 average. That marks a +521% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MREO today (≈ 2,985.074627 MREO) could be worth
$6,206.32
+$5,206.32 (+521%) by 2050 · US Dollar
Based on the average projected MREO price of $2.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MREOwould be worth at today's price.
$1,000 invested in MREO on Jul 10, 2025 (≈ 591.715956 MREO) would be worth
$198.22
-$801.78 (-80.2%) today · 0.20× · US Dollar
Based on a MREO entry price of $1.69 vs. today's $0.335.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.335 | $1,000 | -0.0% |
| 1 month ago | $0.305 | $1,098.36 | +9.8% |
| 3 months ago | $0.329 | $1,018.24 | +1.8% |
| 6 months ago | $0.567 | $590.83 | -40.9% |
| 1 year ago | $1.69 | $198.22 | -80.2% |
| All time (5.0y) ago | $2.82 | $118.79 | -88.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MREO forecast.
Our base-case forecast reaches $0.67 around 2040.
Implied market cap at $0.67: $106.94M
The multi-year forecast shows a path of growth with a clear bullish tilt from 2030 onward. In 2030, the average price is projected at $0.4433 with a max of $0.7358 and a min of $0.2887, yielding a 33.6% ROI and a bullish sentiment. By 2040, the average rises to $0.8355 with a max of $1.72 and a min of $0.399, delivering a 151.8% ROI in a bullish context.
The 2050 projection points to an average of $1.92, a max of $4.41, a min of $0.8626 and a 477.7% ROI, remaining bullish. Earlier years show modest to neutral drift (e.g., 2026 avg $0.3318 and 2027 avg $0.3284), before the material upside emerges from 2030 onward. These figures are estimates and not guarantees, but they outline a scenario of increasing value with substantial potential upside in the long term.
Tap a question to reveal the answer.
In 2030, the forecast average price is $0.4433, with a min of $0.2887 and a max of $0.7358, and the ROI is 33.6% with a bullish sentiment.
Forecasts show neutral in 2026 and 2027, then bullish in 2030 and beyond, with a 33.6% ROI in 2030, 151.8% in 2040, and 477.7% in 2050, indicating potential upside despite near-term uncertainty.
Yes. The 2050 forecast lists a max price of $4.41 with an average of $1.92 and an ROI of 477.7%, under a bullish sentiment.
Current price is $0.3318 and market capitalization is $52.96M, with a rank of 4300.
Sentiment is BULLISH with RSI(14) at 60. The SMA50 is $0.294 and the SMA200 is $0.9594. Support is at $0.237 and resistance at $0.345, with a 30-day range from $0.2447 to $0.45 and annualized volatility of 90%.
Mereo BioPharma Group plc Community Discussion
0Share your Mereo BioPharma Group plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.